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Effects of the new Histone Deacetylase Inhibitor, PXD101, 
 in Bladder Cancer 
Hristos Z. Kaimakliotis, Marcia Wheeler, and Robert M. Weiss, Section of Urology, 
Department of Surgery, Yale University, School of Medicine, New Haven, CT. 
 
Histone deacetylase inhibitors (HDACIs) mediate gene expression and chromatin 
assembly, and induce growth arrest and apoptosis of tumor cells, thus representing a new 
strategy for human cancer therapy. Changes in apoptosis signaling pathways and the effect 
on cell growth and cell-cycle arrest of a new HDACI, PXD101, on T-24 bladder cancer 
cells form the basis of this study. 
T-24 cells were incubated with PXD101 at varying concentrations and times, and 
viable cell count and proliferation curves were constructed. Cell cycle analysis was 
conducted with Fluorescent Activated Cell Sorting and changes in apoptosis signaling 
proteins that were previously found to be regulated by survivin-siRNA in T-24 cells were 
assessed by Western blot. 
Treatment of T-24 bladder cancer cells with the HDAC inhibitor PXD101 causes a 
profound decrease in cell growth and viability, a specific G2/M phase arrest and an 
increase in apoptotic cells populations. PXD101 treatment also causes changes in upstream 
mitochondrial apoptosis mediators, including TNFR1 and caspases 2 and 8, and 
downstream apoptosis mediators, such as caspase 3 and survivin. PXD101 treatment of 
tumor cells is associated with a profound decrease in survivin and caspases’ levels, and 
with an increase in TNFR1 protein levels, both changes indicative of induction of apoptosis. 
Therefore, the new HDACI PXD101, alone or in combination with inhibitors of 
other tumor relevant factors and chemotherapies with complementary mechanisms of 
action, shows promise for its use as a suitable new agent for bladder cancer treatment. 
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Introduction 
A multicellular organism functions as a society, with individual cells organizing 
into collaborative assemblies and reproducing by cell division through an elaborate set of 
signals that serve as controls. Each cell rests, divides, differentiates or dies as needed for 
the prosperity of the organism. Molecular disturbances that upset this harmony mean 
trouble for such a society and in animals with countless cells and disturbances, mutations 
are a constant challenge. A single mutation that goes unchecked may give rise to a 
growing mutant clone of cells that will prosper at the expense of neighboring cells and in 
the end, destroy the entire society. 
Such is the recipe for cancer, and to this day, cancer accounts for nearly one-
quarter of deaths in the United States, exceeded only by heart disease.  In 2003, there 
were 556,902 cancer deaths in the US, Figure 1. The risk of an American male 
developing cancer over his lifetime is one in two and approximately one in three women 
in the United States will develop cancer over her lifetime. 
1. Heart Diseases 685,089 28.0
2. Cancer 556,902 22.7
3. Cerebrovascular diseases 157,689 6.4
4. Chronic lower respiratory diseases 126,382       5.2
5. Accidents 109,277 4.5
6. Diabetes mellitus 74,219 3.0
7. Influenza and pneumonia 65,163 2.7
8. Alzheimer disease 63,457 2.6
9. Nephritis 42,453 1.7
10. Septicemia 34,069 1.4 
Cause of Death No. of deaths
% of all 
deaths
 
Figure 1: United States Mortality Data, Leading Causes of Death for 2003 [1].  
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Bladder Cancer 
It is estimated that almost 1.4 million new cases of cancer were diagnosed in 
2006.  Of these, 61,420 cases were due to urinary bladder cancer, making it the fourth 
most common and ninth most common site of new cancer diagnoses in men and women, 
respectively. Bladder cancer is the second most common genitourinary tract cancer and 
between 1985 and 2000, the number of bladder cancers diagnosed annually in the United 
States increased by 33% [2, 3]. The incidence in men is nearly three times higher than in 
women [3], and 1.5 times higher in whites than in African Americans. Incidence rates in 
Hispanic Americans of each sex are roughly half those in whites [4]. 
Men
720,280
Women
679,510
31% Breast
12% Lung & bronchus
11% Colon & rectum
6% Uterine corpus 
4% Non-Hodgkin
lymphoma 
4% Melanoma of skin
3%     Thyroid
3% Ovary
2% Urinary bladder
2% Pancreas
22% All Other Sites
Prostate 33%
Lung & bronchus 13%
Colon & rectum 10%
Urinary bladder 6%
Melanoma of skin 5%
Non-Hodgkin 4%                      
lymphoma
Kidney 3%
Oral cavity 3%
Leukemia 3%
Pancreas 2%
All Other Sites 18%
 
Figure 2: 2006 Estimated US Cancer Incidence By Site and Sex. Data exclude basal 
and squamous cell skin cancers [5]. 
It was estimated that in 2000 there were 12,200 bladder cancer deaths, 8100 men 
and 4100 women, making bladder cancer the seventh most common cause of cancer 
deaths in American men [3]. Bladder cancer accounts for 2.9% of all cancer deaths in 
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men and 1.5% in women. Even though mortality rates have decreased since the 1970s 
among African Americans and stabilized since the late 1980s among whites [6], an 
estimated 13,060 deaths occurred in 2006, as shown in Figure 3. The 5-year relative 
survival rate for bladder cancer is 83% for whites and 64% for African Americans. The 
survival rate has improved somewhat since the 1970s, mainly due to earlier detection. 
 
Figure 3: Types of cancers in United States, with incidence and resulting death rate. 
 
 
4
 
Findings 
The most common presenting symptom of bladder cancer is painless hematuria, 
which occurs in more than 85% of patients [7]. However, hematuria is often intermittent, 
and the lack of hematuria does not rule out the presence of bladder cancer [8]. If an adult 
has unexplained gross or microscopic hematuria, cystoscopic examination is warranted. 
The symptom complex of bladder irritability and urinary frequency, urgency, and dysuria 
is the second most common presentation and is usually associated with diffuse carcinoma 
in situ or invasive bladder cancer. These symptoms almost never occur without at least 
microscopic hematuria. 
Other signs and symptoms of bladder cancer include flank pain from ureteral 
obstruction, lower extremity edema and pelvic mass. Very rarely, patients present with 
symptoms of advanced disease, such as weight loss and abdominal or bone pain. 
Hepatomegaly and supraclavicular lymphadenopathy are signs of metastatic disease. 
Pyuria may be present, either due to a concomitant infection or inflammation of the 
urothelium around the tumor. Azotemia due to ureteral obstruction or anemia from 
chronic blood loss also may be found. 
Cytologic specimens from bladder washings may allow tumor detection and are 
useful in screening patients or assessing response to treatment. Urine cytology is more 
sensitive in patients with high-grade tumors or carcinoma in situ, but even in patients 
with high-grade tumors, cytology may be falsely negative in as many as 20%of cases. 
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Pathology 
Nearly all bladder cancers are of epithelial origin, with the vast majority being 
transitional cell carcinomas. The urothelium of the normal bladder is three to seven layers 
thick, with a basal cell layer and one or more layers of intermediate cells in between the 
basal layer and the superficial basal layer. The most superficial layer is composed of 
large, flat, umbrella cells and the entire urothelium rests on the lamina propria basement 
membrane. 
Epithelial hyperplasia describes an increase in the number of cell layers without 
nuclear or architectural abnormalities, whereas urothelial metaplasia refers to a non-
transitional epithelial appearance of the bladder lining, with associated squamous or 
adenomatous metaplasia. Atypical hyperplasia is similar to epithelial hyperplasia, except 
that there are also nuclear abnormalities and a partial derangement of the umbrella cell 
layer [9]. The term dysplasia denotes epithelial changes that are intermediate between 
normal urothelium and carcinoma in situ. Dysplastic cells have large, round, notched, 
basally situated nuclei that do not exhibit the normal epithelial polarity. Dysplastic 
epithelium does not have an increased number of cell layers or mitotic figures [7], but a 
large portion of patients with moderate dysplasia tend to develop high-grade urothelial 
cancer [10]. 
Carcinoma in situ may appear cystoscopically as a velvety patch of erythematous 
mucosa, although it may be endoscopically invisible. It consists of a poorly differentiated 
transitional cell carcinoma confined to the urothelium, Figure 4. Carcinoma in situ may 
be asymptomatic or may produce severe symptoms of urinary frequency, urgency and 
dysuria. Urine cytopathology is positive in 80% to 90% of patients with carcinoma in situ 
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[11]. Carcinoma in situ is present in 25% or more of patients with high-grade superficial 
tumors [9],  and between 40 and 83% progress to muscle-invasive cancer[12]. It also is 
present in 20 to 75% of high-grade muscle-invasive cancers [13]. About 20% of patients 
treated with cystectomy for diffuse carcinoma in situ are found to have microscopic 
muscle-invading cancer [14]. 
 
Figure 4: Carcinoma in situ [15]. 
 
Transitional Cell Carcinoma 
The most common bladder cancers are transitional cell (TCC), squamous cell and 
adenocarcinomas. More than 90% of bladder cancers are TCC, which exhibit an 
increased number of epithelial cell layers with papillary foldings of the mucosa, loss of 
cell polarity, abnormal cell maturation with increased nuclear-cytoplasmic ratio, 
prominent nucleoli, clumping of chromatin and increased number of mitoses. TCC 
manifests in a variety of patterns of tumor growth, including papillary, sessile, 
infiltrating, nodular, mixed, and flat intraepithelial growth (carcinoma in situ). 
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Approximately 70% of bladder tumors are papillary, 10% are nodular and 20% are 
mixed. 
No uniformly accepted grading system for TCC exists, but most systems are 
based on the degree of anaplasia of tumor cells [16, 17]. A strong correlation exists 
between tumor grade and stage [18], with most well-differentiated and moderately 
differentiated tumors being superficial and most poorly differentiated tumors being 
muscle invasive. There is a significant correlation between tumor grade and prognosis, 
however, the correlation between tumor stage and prognosis is even stronger. 
 
Nontransitional Cell Carcinomas 
Squamous cell carcinoma accounts for only 5% of bladder cancers in Europe and 
the United States [19, 20], but as much as 75% in Egypt, where Schistosoma 
haematobium cystitis is causally related to the development of squamous cell carcinoma 
of the bladder [21]. Adenocarcinomas account for less than 2% of primary bladder 
cancers [20], and are prevalent in intestinal urinary conduits, augmentations, neobladders 
and bladder exstrophy [22]. About 5% of all cases are mixed, and other epithelial cancers 
include carcinoid, carcinosarcomas and melanomas. Rare nonepithelial cancers of the 
bladder include pheochromocytomas, choriocarcinomas and mesenchymal tumors.  
 
Causes 
Chemical carcinogens have been implicated in the pathogenesis of bladder cancer, 
but there are undoubtedly a large portion of cases with no obvious exposure to such 
agents. Occupational exposure accounts for roughly 20% of bladder cancer cases in the 
United States [23], and the latency period is around 30-50 years, with more intensive 
exposures leading to shorter latency periods [24]. Most bladder carcinogens are aromatic 
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compounds. Nevertheless, the list is non-exhaustive, from aniline dyes [25], to 
combustion gases and soot from coal, chlorinated aliphatic hydrocarbons [26], dietary 
nitrites and nitrates [27] and aldehydes used in the rubber and textile industries [28].  
Although the mechanisms of carcinogenesis in the presence of inflammation are 
not understood [29] there appears to be a clear association of inflammation and squamous 
cell carcinoma of the bladder. Chronic cystitis in the form of severe, long-term infections 
leads to an increased risk [30]. There also is an association with the presence of long-term 
indwelling catheters, since 2-10% of paraplegics with long-term indwelling catheters 
develop malignancy.  Cigarette smoking also has been reported to be significantly 
associated with an increased risk of transitional and squamous cell bladder carcinomas 
[31], leading to a fourfold higher incidence of bladder cancer compared to people who 
have never smoked [32, 33], with the risk correlating with the number of pack years. 
Use of cyclophosphamide leads to a ninefold increased risk of developing bladder 
cancer [32], with a relatively short latent period between 6 and 13 years. These are high 
grade and muscle infiltrating tumors at the time of diagnosis, with an equal incidence in 
both sexes [34]. The urinary metabolite acrolein is believed to be the responsible agent 
[35], and mesna, 2-mercaptoethanesulfonic acid, reduces the risk of bladder cancer in 
patients who develop hemorrhagic cystitis [36]. 
Specific genetic associations are still unknown, but are likely to involve activation 
of oncogenes or loss of function of tumor suppressor genes. Some of the most common 
genetic abnormalities identified in bladder cancer include loss of chromosomes 11p or 
17p, which map to the proto-oncogene c-ras and the tumor suppressor gene p53, 
respectively[37]. 
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Natural History 
Malignant transitional cells invading the lamina propria and the muscularis 
propria can gain access to blood vessels and lymphatics. Roughly 5% of patients with 
well-differentiated or moderately differentiated superficial papillary cancer and 
approximately 20% with high-grade superficial disease (including carcinoma in situ) 
ultimately manifest vascular or lymphatic spread, indicating that many patients with 
superficial malignancies have their initial lesion pathologically understaged and already 
harbor muscle-invading disease [38]. 
In the United States, about 60% of all newly diagnosed bladder cancers are well-
differentiated or moderately differentiated, superficial papillary TCC [39]. The majority 
of these patients develop tumor recurrences after endoscopic resection, with up to 25% 
recurring as higher-grade tumors [13]. Approximately 10% of patients with superficial 
papillary tumors subsequently develop invasive or metastatic cancer [11, 12], even after a 
prolonged tumor-free remission of over 5 years [10]. 40% of newly diagnosed bladder 
cancers are high-grade lesions, more than half of which are muscle invading or more 
extensive at the time of diagnosis [39]. High-grade superficial tumors tend to recur and 
develop invasive and metastatic disease far more frequently than low-grade tumors [38]. 
Most patients with occult metastases develop overt clinical evidence of distant 
metastases within 1 year [40]. The common sites of metastases are liver, 38%, lung, 36%, 
bone, 27%, adrenal glands, 21%, and intestine, 13% [15]. High grade disease also spreads 
by implantation in abdominal wounds or denuded urothelium [41]. Despite advances in 
treatment of systemic urothelial cancer, few patients with distant metastases survive 5 
years [42]. 
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Staging and Treatment 
Because tumor stage is important in determining therapy, accurate staging of 
bladder cancer is desirable. The main staging system of bladder cancer, also termed 
Tumor-Node-Metastasis system (TNM), has been revised and developed by the 
International Union Against Cancer and the American Joint Committee on Cancer [43]. 
 
Table 1: TNM Staging System for Bladder Cancer 
 
PRIMARY TUMOR (T) Treatment Option 
Single, low grade, non-
recurrent 
Complete Transurethral resection (TUR) Ta Noninvasive 
papillary 
carcinoma Multiple, high grade, or recurrent 
Complete TUR followed by intravesical  BCG 
or chemotherapy 
Tis Carcinoma in situ: flat tumor Complete TUR followed by intravesical BCG 
T1 Tumor invades lamina propria Complete TUR followed by intravesical  BCG or chemotherapy 
T2 Tumor invades muscle 
T2a Tumor invades superficial muscle 
T2b Tumor invades deep muscle (outer half) 
T3 Tumor invades perivesical fat 
T3a Microscopically 
T3b Macroscopically (extravesical mass) 
T4 Tumor invades prostate, uterus, vagina, 
pelvic wall, or abdominal wall 
T4a Tumor invades prostate, uterus, vagina 
T4b Tumor invades pelvic or abdominal wall 
 
Radical cystectomy 
or 
Neoadjuvant chemotherapy followed by radical 
cystectomy 
or 
Radical cystectomy followed by adjuvant 
chemotherapy 
or 
Neoadjuvant chemotherapy followed by 
irradiation 
 
NODAL INVOLVEMENT (N) 
N0 No regional lymph node metastasis  
N1 Metastasis in a single lymph node, 2 cm 
or less in greatest dimension 
N2 Metastasis in a single lymph node, more 
than 2 cm but not more than 5 cm in 
greatest dimension, or multiple lymph 
nodes, none more than 5 cm in greatest 
dimension 
N3 Metastasis in a lymph node more than 5 
cm in greatest dimension 
 
 
 
Systemic chemotherapy followed by selective 
surgery or irradiation 
DISTANT METASTASIS (M) 
M0 No distant metastasis  
M1 Distant metastasis Systemic chemotherapy followed by selective surgery or irradiation 
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Bladder cancer remains a therapeutic challenge, where cystectomy, systemic 
chemotherapy, radiation, intravesical treatment or a combination of these comprise the 
spectrum of interventions. Treatments begin from transurethral resection and intravesical 
therapy of superficial bladder tumors, as indicated in Table 1, and include selective 
surgical cystectomy procedures, before or after chemotherapy or irradiation for muscle 
invasive disease.  
Intravesical instillation with Bacillus Calmette-Guerin (BCG) has proven to be an 
effective treatment for superficial bladder cancer and for CIS for the last twenty five 
years, even though the exact mechanism of action remains unknown [44]. Mitomycin C, 
an antibiotic that inhibits DNA synthesis, is equivalent to BCG for superficial disease in 
terms of survival rates [45]. Radical cystectomy is the treatment of choice for muscle-
invasive bladder cancer, however, only half of these patients will be cured by cystectomy 
alone [46]. Systemic chemotherapy involves MVAC, methotrexate, vinblastine, 
adriamycin and cisplatin, which has been the standard combination regimen for nearly 
two decades. For locally advanced and metastatic bladder cancer, long-term survival is 
rare. Average survival for patients receiving MVAC is less than 14 months, and 
approximately 4% remain disease-free at 5 years [47]. Newer agents, such as 
gemcitabine, have a single-agent response rate of approximately 25% [48]. 
Even though the mortality rates for bladder cancer have improved over the last 
thirty years, it is estimated that 13,060 patients in 2006 succumbed of the disease. Current 
forms of therapy for invasive tumors are limited and there has been little improvement 
over the last two decades. These daunting statistics beckon for new and better treatment 
modalities [49]. 
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Histone Deacetylase Inhibitors as a New Cancer Treatment 
Evidence for epigenetic events associated with tumorigenesis centers around 
DNA methylation and histone acetylation [50]. Post-translational modifications of 
histones, such as acetylation, phosphorylation and methylation, play an important role in 
chromatin structure and function and in the regulation of gene expression [51]. Histone 
acetylation is regulated by two families of enzymes, histone acetyl transferases (HATs) 
and histone deacetylases (HDACs), which catalyze, respectively, the addition or the 
hydrolysis of acetyl groups to lysine residues of nucleosomal histones [52]. The opposing 
actions of HATs and HDACs allow gene expression to be exquisitely regulated. 
Histone hypo-acetylation is involved in the tumorigenesis of many malignancies, 
and inhibition of HDACs poses as a new strategy in human cancer therapy. To date, 
many HDAC inhibitors (HDACIs) have been developed and have been shown to be 
potent inducers of tumor growth arrest, differentiation and apoptosis of tumor cells in 
vitro and in cancer patients in phase I and II clinical trials [53]. Although the precise 
mechanisms underlying these cellular responses to HDACIs have yet to be characterized, 
HDACI efficacy may be due at least in part to suppression of cancer cell migration, 
invasion, metastasis, blood supply and angiogenesis [53]. 
There are several structurally diverse classes of HDACIs. These include short-
chain fatty acids, cyclic and non-cyclic hydroxamates, cyclic peptides or tetrapeptides, 
benzamides, ketones and hybrids of hydroxamic acid and cyclic tetrapeptide. One of the 
first known HDACI was sodium N-butyrate [54], a potent growth inhibitor and 
differentiating agent for many tumor cell lines. During initial clinical trials, limited 
efficacy was observed with some toxicity and Phase II clinical trials are still on-going. 
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Phenylacetate and phenylbutyrate gave the same results, as well as the anti-epileptic 
agent, valproic acid, which has been reported to delay the growth of primary breast 
cancers and to act against metastases found in the lung [55]. However, all these 
compounds are weak inhibitors, even in high concentrations and non-selective, with 
pleiotropic effects [56]. 
 
Histone Deacetylase Inhibitors and Bladder Cancer 
T-24 cells are poorly differentiated bladder urothelial cells, derived from an 
invasive high-grade bladder tumor with metastatic potential [57]. When treated with 
several HDACIs, such as suberoylanilide hydroxamic acid or Trichostatin A, T-24 cells 
show changes in a core set of genes that are involved in cell cycle progression, DNA 
synthesis and apoptosis [58]. Specific changes include an up-regulation of tumor 
suppressor p21, an accumulation of cells in the G2/M phase of the cell cycle and a 
decrease in survivin levels [59]. p21 is aberrantly expressed in bladder cancer [60] and 
when activated, modulates survivin expression [61, 62]. 
Survivin is a member of the family of inhibitors of apoptosis proteins (IAP), and 
is expressed in nearly all human carcinomas, including TCC, but not in terminally 
differentiated adult tissues [63]. It is highly expressed in bladder cancer and bladder 
cancer cell lines, but not in normal urothelium or in cultured urothelial cells [64, 65], and 
its expression in bladder tumors correlates with abbreviated survival [64]. Furthermore, 
the presence of survivin protein and mRNA in urine [66] correlates with the presence of 
TCC and that when measured in subjects following intravesical BCG or mitomycin C 
treatment, survivin may serve as a marker for recurrent disease [67]. 
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As a pilot study in the Weiss lab, T-24 cells were treated with valproic acid, a 
relatively weak HDACI with inhibitor activity in the millimolar range, to assess effects 
on the IAP survivin (Justin Cohen, unpublished results).  Incubation of T-24 cells with 10 
mM valproic acid for 24 and 48 hrs caused a 65 and 57% decrease in cell proliferation, 
respectively, and reduced survivin protein levels by approximately 50% relative to actin 
protein levels at 0.1 mM (Figure 5).  
 
Figure 5: Effect of Valproic acid on survivin levels in T-24 cells at 24 hours. 
Given the importance of this IAP, the Weiss lab and others have investigated the 
possibility of a new cancer treatment strategy for TCC by reducing the levels of survivin 
using RNA interference [68]. This is a process by which a 20-25 nucleotide small 
interference RNA (siRNA) can lead to specific gene silencing by forming a RNA-
induced silencing complex with double-stranded RNA. Because survivin is important in 
bladder cancer tumorigenesis, this new technique has implications for gene therapy of 
TCC. This led to siRNA-mediated down-regulation of survivin in two bladder cancer cell 
 
 
15
lines, which was associated with reduced viability, a specific G2/M arrest, the induction 
of apoptosis, the occurrence of multi-nucleated cells and an increase in cytosolic 
cytochrome c, a marker of mitochondrial damage. The Weiss group also investigated the 
effects of survivin-siRNA on T-24 bladder cancer cells using microarray analysis of a set 
of 114 apoptosis related genes. Significant decreases were noted in 14 genes, as shown in 
Table 2. 
Inhibitors of Apoptosis (IAPs) 
Survivin siRNA/ 
Scramble SiRNA ratio 
BIRC5 SURVIVIN 0.02 
TNF receptors & genes related to NF-κB signaling  
TNFRSF25 DR3/Apo-1/cd95 (TNF RECEPTOR SUPERFAMILY MEMBER 25) 0.18 
TNFRSF1A TNFR1  (TNF RECEPTOR SUPERFAMILY MEMBER 1A) 0.40 
LTBR LYMPHOTOXIN β RECEPTOR(TNF RECEPTOR SUPERFAMILY MEMBER 3) 0.46 
TRADD TNFRSF1A-ASSOCIATED VIA DEATH DOMAIN 0.74 
Caspases and related genes  
CARD10 CASPASE RECRUITMENT DOMAIN FAMILY MEMBER 10 0.17 
CASP4 CASPASE-4, APOPTOSIS-RELATED CYSTEINE PROTEASE 0.31 
CASP2 CASPASE-2, APOPTOSIS-RELATED CYSTEINE PROTEASE  ICH-2 0.31 
Akt/PKB & related genes  
 Akt /PKB   Akt / PKB  (v-Akt MURINE THYMOMA VIRAL ONCOGENE HOMOLOGUE 1) 0.14 
ABL1 c-Abl (v-Abl ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOGUE 1) 0.20 
Bcl-2 related genes  
BCL2L11       BCL2-LIKE11 (APOPTOSIS FACILITATOR,  BimL) 0.15 
BCL2L13 BCL2-LIKE 13 (APOPTOSIS FACILITATOR) 0.19 
BNIP1 NIP-1 (BCL2/ADENOVIRUS E1B 19 kDa INTERACTING PROTEIN 1) 0.19 
BCL2L12 BCL2-LIKE 12 (APOPTOSIS FACILITATOR) 0.21 
BAK1 Bak (BCL2 -ANTAGONIST/KILLER 1) 0.29 
Housekeeping genes  
GAPD GAPDH 0.85 
ACTB BETA- ACTIN 0.97 
Table 2: Changes in apoptotic gene products after treatment of T-24 cells with 
survivin-siRNA for 72 hours. 
Downregulation of survivin in T-24 cells using survivin-siRNA is associated with a 
decreased cell growth, a specific G2/M arrest, an increase in cytochrome-c release and 
altered production of genes related to apoptosis, including four TNF receptors [69], three 
caspases, and the Bcl-2 related gene, BAK1 [65]. 
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A new Histone Deacetylase Inhibitor, PXD101 
PXD101 is a new hydroxamate HDACI developed by TopoTarget Prolifix in the 
UK and Curagen in the US. PXD101 was found to inhibit HDAC activity in HeLa 
extracts with an IC50 value of 27 nM. It also inhibited HDAC activity in various cell 
lysates from ovary, colon, lung or breast with an IC50 in the 9–100 nM range. Antitumor 
activity at a dose of 10 mg/kg daily was observed in xenografts of the human ovarian cell 
line A2780, with no effect on body weight or apparent toxicity to the mice at ≤40 mg/kg. 
Antitumor activity was also noted [70] in cell lines relatively resistant to current 
cytotoxic drugs. PXD101 is well tolerated in rodents and non-rodents and orally 
bioavailable in dogs. PXD101 entered Phase I clinical trials at the end of 2003 [71]. 
Synergism with cis-platin and 5-Fu has also been reported [72]. 
 
 
Figure 6: Histone Deacetylase Inhibitor, PXD101 
No significant improvement in the treatment of bladder cancer has occurred in the 
past two decades and therefore new modalities of treatment are needed. Survivin is highly 
expressed in TCC, and its down-regulation causes profound changes in mitosis and 
apoptosis, which may be related to changes in TNF receptors. HDAC inhibitors inhibit 
the growth of bladder cancer cells, and also downregulate survivin and other anti-
apoptotic proteins in cancer cells. Therefore, we propose to study the effects of PXD101 
on survivin levels in T-24 bladder cancer cells, as the chemopreventative role of this new 
HDACI may involve down-regulation of survivin and other apoptotic signaling proteins.  
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Statement of Purpose 
Bladder cancer remains a therapeutic challenge as current forms of therapy for 
invasive tumors are limited. Daunting statistics beckon for new and better treatment 
modalities.  HDACIs mediate gene expression and chromatin assembly, and induce 
growth arrest and apoptosis of tumor cells, thus representing a new strategy for human 
cancer therapy. HDACIs inhibit the growth of bladder cancer cells, and also 
downregulate survivin and other anti-apoptotic proteins in cancer cells.  Survivin is 
highly expressed in TCC and down-regulation of survivin causes profound changes in 
mitosis and apoptosis. Therefore, changes in apoptosis signaling pathways and the effect 
on cell growth and cell-cycle arrest of a new HDACI, PXD101, on T-24 bladder cancer 
cells form the basis of this study. 
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Materials and Methods 
All experiments and data analysis were conducted by Hristos Z. Kaimakliotis. 
Materials: Anti-survivin polyclonal antibody was purchased from 
NovusBiologicals, Inc, Littleton, CO. Anti-caspase-8 monoclonal antibodies was 
purchased from Cell Signaling Technology, Beverly, MA. Anti-actin goat polyclonal and 
anti-TNFR1 monoclonal antibodies were purchased from Santa Cruz Biotechnology. 
Anti-caspase-3 polyclonal antibody was purchased from R&D Systems, Inc. Anti-
caspase-2 polyclonal antibody was purchased from BD Pharmingen Bioscience, San 
Diego CA. Anti-Bak polyclonal antibody was purchased from Upstate, Charlottesville, 
VA. Peroxidase-conjugated affiniPure F(ab’)2 fragment donkey anti-rabbit IgG and rat 
anti-mouse antibodies were purchased from Jackson ImmunoResearch Laboratories, 
West Grove, PA. 
Preparation of cells treated with PXD101: T-24 cells were plated on 6 well 
plates in McCoy’s media with serum and glutamate. Cells were treated after 24 hours, 
when they were 30-50% confluent. Cells were incubated with PXD101 for up to 72 
hours, then trypsinized, treated with trypan blue and counted or prepared for Western blot 
or FACS cell sorting. 
FACS of propidium iodide (PI) treated cells: Trypsinized cells were washed 
with PBS and fixed with 95% ethanol. Two hours prior to cell sorting, ethanol was 
removed after centrifugation. Since RNA also binds PI, cells were treated with 400 μg 
RNAse type 1A (Sigma, St. Louis, MO) at 37°C for 30 minutes, followed by PI (50 
μg/ml) for 45 minutes (4°C).  Cells were sorted and analyzed with ModFit to determine 
DNA content. 
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Western blot analysis: After removal of media, 20 mmol/L Tris buffer (pH 7.4) 
containing 1 mmol/L EDTA, 1 mmol/L EGTA, 1% triton X-100, phosphatase and 
protease inhibitors, was added to culture wells to lyse the cells (10 minutes, 4°C). Then, 
2x SDS sample buffer with 5% β-mercaptoethanol was added, cells were scraped and 
collected. Pairs of samples were normalized for each time point and concentration of 
PXD101, based on actin quantification determined after Western blot. To normalize the 
samples, standard loading volumes were used and samples were subjected to Western 
blot analysis and normalized volumes were determined by adjusting loading volumes 
with respect to actin immunoreactivity of the protein bands on the resulting blot.  
For all Western blots, after separation of proteins by SDS-PAGE, proteins are 
transferred to nitrocellulose membranes. After incubation with the appropriate primary 
and secondary antibodies, immunoreactive proteins were detected using 
chemiluminescence (ECL, Amersham Biosciences, Uppsala, Sweden). Band densities 
from photographic film of the blot were quantified using digital image analysis (Eastman 
Kodak Company, Rochester, NY). 
Cell proliferation assay: Cell proliferation in the presence and absence of the 
HDACI, PXD101 was measured by the cleavage of the tetrazolium salt WST-1 to 
formazan by mitrochondrial dehydrogenases (EMD Bioscience, Darmstadt, Germany). 
Statistics: For each experiment a PXD101 concentration curve was constructed, 
using vehicle in control samples. Results of at least 3 different experiments performed in 
duplicate were expressed as a mean % change over control ± SEM. Significance was 
determined by ANOVA (p<0.05). 
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Results 
 
 
Changes in apoptosis signaling pathways and the effect on cell growth and cell-
cycle arrest of the new HDACI, PXD101, on T-24 bladder cancer cells form the basis of 
this study and results are presented below.  
 
Cell Proliferation and Viable Cell Counts 
T-24 cells were incubated with PXD101 at varying concentrations and times, and 
proliferation and viable cell count curves were constructed. In the presence of 5 μM 
PXD101 for 48 hours, T-24 cells exhibited a 56.7% ± 4.2 decrease in proliferation 
(Figure 7). 
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Figure 7: T-24 cell inhibition at 48 hours in presence of PXD101. 
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In the presence of 5 μM PXD101 for 72 hours, T-24 cells exhibited a 64.8% ± 3.2 decrease in 
proliferation (Figure 8). 
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Figure 8: T-24 cell inhibition at 72 hours in presence of PXD101. 
 
Viable cell counts of T-24 cells incubated for 24 and 48 hours with 5 μM 
PXD101 decreased by 30.6% ± 4.8 and 89.0% ± 3.0, respectively. The IC50 of PXD101 
for proliferation and viable cell counts was approximately 1 μM (Figure 9). 
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Figure 9: T-24 viable cell counts in presence of PXD101 for 24 hrs and 48 hrs. 
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FACS Analysis 
Cell cycle analysis was conducted with FACS. Treatment of T-24 bladder cancer 
cells with PXD101 (2 and 5 μM, 48 hrs) increased apoptotic cells (sub-G1 cells) 1.3 and 
2.3 fold, respectively (Figure 10). Apoptotic cells appeared as a distinct population of 
decreased size and cell density, as expected.  
 
Figure 10: T-24 bladder cancer cells FACS scatter plots of control (left) vs. treated 
(right, 5 μM PXD 101 for 48 hours). 
 
The untreated gated control population was used for cell-cycle population analysis 
and comparison, and cell distributions. All changes reported in Table 3 are significant. T-
24 bladder cancer cells treated with PXD101 (1, 2 and 5 μM, 48 hrs) decreased G1 phase 
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cells by 41-54% and increased S and G2/M phase cells 2.5-3.5 fold (Figure 11). No 
significant changes in cell cycle distribution were noted at 12 or 24 hours. 
 Time 
(hr) 
0μM  PDX101 1μM PDX101 2μM PDX101 5μM PDX101 
Cell Cycle Changes over Control 
G0/G1 phase 48  -41.2% + 3.8 -53.7% + 3.1 -53.9% + 0.9 
S phase 48  +287.4%+127.4 +343.0%+125.7 +364.8%+124.3 
G2/M phase 48  +250.5%+29.8 +271.3%+33.3 +321.5%+39.1 
Cell Cycle Distribution 
G0/G1 phase 48 84.2.0%+2.9 49.3%+2.2 40.1% + 2.0 38.9% + 1.9 
S phase 48 5.5% + 1.8 14.4%+0.5 17.5% + 1.4 18.8% + 1.8 
G2/M phase 48 7.9% + 1.3 27.9%+2.7 28.8% + 2.6 33.6% + 3.6 
Table 3: FACS analysis of cell cycle distribution and changes in T-24 bladder cancer 
cells treated with PXD101. 
 
Figure 11 shows a representative FACS cell-cycle histogram, comparing treated 
vs. untreated cells at 48 hours. 
 
Figure 11: T-24 bladder cancer cells FACS cell-cycle histogram of untreated (red) 
vs. treated (green, 5 μM PXD 101 for 48 hours). 
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Western Blot Analysis 
Changes in apoptosis signaling proteins that the Weiss laboratory previously 
found to be regulated by survivin-siRNA in T-24 cells (See Table 2) were assessed by 
Western blot in this study for effects by HDACI PXD101 in T-24 cells. These proteins 
included survivin, caspases 2, 3 and 8, BAK1 and TNFR1. Actin levels were used to 
normalize across varying concentrations, as it remains unchanged during induction of 
apoptosis. Representative blots of each protein assessed are shown in Figure 12 and all 
protein level changes are shown in Figures 14 & 15 and are reported in Table 4. 
Actin
43kDa
Survivin
16kDa
Caspase 2
48kDa
Caspase 3
32kDa
Caspase 8
43kDa     
BAK1
30kDa
TNFR1
55kDa
Conc (μM) 0 0.01 0.05 1.0 2.0 5.0
Figure 12: Representative western blots showing actin, survivin, caspases 2, 3 and 8, 
BAK1 and TNFR1 levels in T-24 bladder cancer cells treated with PXD101 for 48 
hours (experiments were repeated three times for a total n=6). 
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The caspases were analyzed using the higher molecular weight pro-caspase band, 
even though the active protein is the lower molecular cleaved product. One antibody is 
used for each pro-caspase/caspase pair in question, and although directed at the pro-
caspase band, binds both at different rates. The presence of cleaved (activated) caspase 
was visualized for all three caspases, but only at long film exposures, which deterred its 
quantitative analysis due to over-exposure and appearance of non-selective binding  
(Figure 13). Decrease in the levels of pro-caspase with the concomitant increase of 
cleaved activated product indicates up-regulation of caspase pathways and induction of 
apoptosis.  
 
 
Figure 13: Representative western blots of pro-caspases 2, 3 and 8 with their 
respective activated cleaved products in T-24 bladder cancer cells treated with 
PXD101 for 48 hours (experiments were repeated three times for a total n=6).  
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All changes in protein levels are shown in Figures 14 & 15 and are reported in 
Table 4. Incubation of T-24 cells with PXD101 for 24 hours decreased protein levels of 
survivin by 30-60% between 0.5-5 μM, and pro-caspase 2 levels by 43.7 ± 11.9% at 5 
μM. The protein levels of TNFR1 and pro-caspase 8 were increased with low 
concentrations of PDX101 at 24 hours (TNFR1: 112.9 ± 26.1% and 77.9 ± 13.9% at 0.1 
and 0.5 μM; pro-caspase 8: 140.7 ± 1.5%; 0.5 μM), whereas the protein levels of pro-
caspase 3 and of the Bcl2 related protein, BAK1, showed no significant change at 24 
hours (Figure 14). 
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Figure 14: Changes in levels of apoptosis related proteins, survivin, caspases 2, 3 
and 8, BAK1 and TNFR1, in T-24 cells treated with PXD101 at 24 hours (data was 
generated by quantifying Western blots from three separate experiments, n=6). 
 
As in the 24 hour experiment, incubation of T-24 cells with PXD101 for 48 hours 
increased protein levels of TNFR1 by 123.0 ± 62.9% at the low concentration of 0.1 μM. 
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Incubation with higher concentrations of PXD101 for 48 hours decreased the levels of all 
the other proteins tested, as shown in (Figure 15). 
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Figure 15: Changes in levels of apoptosis related proteins survivin, caspases 2, 3 
and 8, BAK1 and TNFR1, in T-24 cells treated with PXD101 at 48 hours (data was 
generated by quantifying Western blots from three separate experiments, n=6). 
Table 4: Relative change in apoptosis proteins survivin, BAK1, TNFR1, caspases 2, 3 and 8, 
in T-24 cells treated with PXD101 at 24 and 48 hours (red indicates significant changes, n=6). 
 Time 
(hr) 
0.1mM 
PDX101 
0.5mM 
PDX101 
1mM 
PDX101 
2mM 
PDX101 
5mM 
PDX101 
BAK1 24 1.7% + 17.4 1.8% + 18.2 -7.8% + 16.1 2.3% + 10.0 -23.9% + 12.2 
Caspase 3 24 5.4% + 15.8 22.3% + 11.1 7.8% + 13.8 1.0% + 10.3 -28.8% + 10.2 
Caspase 2 24 10.0% + 0 0.5% + 0.1 -16.9% + 1.5 -18.3% + 5.4 -43.7% + 11.9 
Caspase 8 24 22.1% + 3.8 140.7%+ 1.5 66.8% + 57.4 17.8%+ 22.6 -36.2% + 15.7 
Survivin 24 1.4% + .08 -30.5% + 1.6 -47.1% + 7.0 -52.6% + 2.1 -59.8% + 5.7 
TNFR1 24 112.9%+ 26.1 77.9% + 13.9 -19.5% + 25.9 0.8% + 26.2 -48.8% + 16.1 
BAK1 48 5.7% + 6.7 5.6% + 7.3 -0.9% + 5.7 -4.3% + 7.0 -38.8% + 8.8 
Caspase 3 48 -9.4% + 7.4 -26.6% + 7.7 -46.8% + 3.8 -50.2% + 9.9 -60.2% + 8.8 
Caspase 2 48 -8.0% + 3.3 -16.0% + 13.7 -38.0% + 17.7 -40.3% + 6.2 -73.1% + 15.6 
Caspase 8 48 10.0% + 7.9 18.5% + 14.7 -20.1% + 14.9 -42.0% +13.5 -79.6% + 11.6 
Survivin 48 -0.5% + 5.6 -2.4% + 15.0 -62.6% + 10.5 -90.2% + 3.2 -94.7% + 3.0 
TNFR1 48 123.0%+ 62.9 75.0% + 47.8 37.0% + 34.3 -4.0% + 35.8 -100% + 1.0 
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Discussion 
Even though the mortality rates for bladder cancer have improved over the last 
thirty years, it is estimated that over thirteen thousand patients succumbed to the disease 
in 2006. Current forms of therapy for invasive tumors are limited and there has been little 
improvement over the last two decades. These daunting statistics beckon for new and 
better treatment modalities [49]. 
Histone deacetylase inhibitors (HDACIs) represent a new strategy for human 
cancer therapy, as they mediate gene expression and chromatin assembly, and induce 
growth arrest and apoptosis of tumor cells. HDACIs also down-regulate survivin, which 
is highly expressed in TCC. The Weiss group has previously shown that down-regulation 
of survivin in T-24 cells using survivin-siRNA is associated with a decreased cell growth, 
a specific G2/M arrest and altered production of genes related to apoptosis, including 
TNF receptors [69], caspases, and Bcl-2 related genes [65]. Cytochrome c release into the 
cytoplasm, the central gate in the activation of apoptosis, was also increased, indicative of 
mitochrondrial damage [65]. 
Many of these apoptosis related changes have been reported by the use of several 
HDACIs in various cancer cell lines. Therefore, changes in apoptosis signaling pathways 
and the effect on cell growth and cell-cycle arrest of a new HDACI, PXD101, on T-24 
bladder cancer cells formed the basis of this study. Western blot analysis of survivin, 
caspases 2, 3 and 8, Bcl-2-antagonist/killer 1 (BAK1) and TNF receptor superfamily 
member 1 (TNFR1) was performed. These proteins were chosen for protein analysis 
because of their high level of gene product expression in T-24 cells and their profound 
down-regulation when T-24 cells are subjected to survivin-siRNA treatment [65]. 
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In the presence of 5 μM of the new HDACI, PXD101 for 48 and 72 hrs, T-24 
bladder cancer cells exhibited 57 and 65% decreases in proliferation, respectively. This 
decrease in proliferation is greater than changes reported with use of other HDACIs, 
including valproic acid and phenylbutyrate, at concentrations in this range [73]. Viable 
cell counts at 24 and 48 hrs (5 μM) were also decreased by 31 and 89% respectively, and 
the IC50 of PXD101 for proliferation and viable cell counts was approximately 1 μM at 
48 hours. This is higher than results found in HeLa extracts with an IC50 value of 0.03 
μM and various cell lysates from ovary, colon, lung and breast with an IC50 in the 0.1 μM 
range [73]. Nonetheless, this relatively low IC50 of PXD101 compared to other agents 
may allow it to be used at lower concentrations, with a lower side effect profile. 
Although no changes in cell cycle distribution were noted at 12 or 24 hours, 
treatment of T-24 cells with PXD101 for 48 hours at 2 and 5 μM increased apoptotic cells 
(sub-G1 cells) 1.3 and 2.3 fold, respectively. Apoptotic cells appeared as a distinct 
population of decreased size and cell density, as expected. These dying cells were 
excluded from analysis of the rest of the cell-cycle phases to provide accurate comparison 
between live cells of treated and control samples. PXD101 at 1, 2 and 5 μM for 48 hrs, 
decreased G1 phase cells by 41-54% and increased S and G2/M phase cells between 2.5-
3.5 fold. This indicates that mitosis is incomplete, with a specific arrest at the G2/M 
phase. These results are consistent with other HDACIs’ activity and is in accord with the 
arrest seen when survivin is down-regulated by treatment with survivin-siRNA in T-24 
cells [65], hepatocellular carcinoma cells, human sarcoma cells [68] and HeLa cells [74]. 
As expected, the protein levels of survivin in T-24 cells treated with PXD101 are 
decreased by 30-60% with 0.5-5 μM PXD101 at 24 hours, and by 62-94% with 1-5 μM 
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PXD101 at 48 hours. These changes are consistent with survivin-siRNA and other 
HDACI induced down-regulation of survivin [65], and lead to the apoptotic changes and 
cell death described earlier, as the IAP is no longer exhibiting its effect in tumor cells. 
On the other hand, the TNFR1 protein is dramatically up-regulated at 24 hours of 
treatment with PXD101 at low concentrations. TNFR1 is increased 113 and 78% with 0.1 
and 0.5 μM at 24 hours, and 123.0% at 48 hours with 0.1 μM PXD101. TNF is tumor 
necrosis factor and increases in TNF receptors and related proteins are considered pro-
apoptotic. Up-regulation of TNFR1 and its ligand TNFα, have been shown to occur when 
apoptosis is induced in leukemic cell with the HDACI, depsipeptide (FK228) [75], 
further demonstrating the efficacy of PXD101 as an anti-tumor agent. 
Activation of the death domain containing receptors, TNF receptor superfamily, is 
associated with activation of the caspase cascade, cytochrome c release, and apoptosis. 
To activate TNF receptors, specific adaptor proteins such as FAS-associated death 
domain (FADD) or receptor-interacting protein [RIP]-associated ICH-1/CED-3-
homologous protein with a death domain (RAIDD/CRADD) bind to ligand-bound 
receptor complexes. Interaction between these adaptor proteins and the prodomain of 
initiator caspases 2, 8 or 10 triggers sequestration-mediated auto-activation of these 
caspases.  These caspases, in turn, cleave and activate downstream caspases 3, 6, and 7 
and trigger apoptosis (Figure 16, page 31). 
Up-regulation of TNFR1 is reversed at higher concentrations of PXD101 and a 
dramatic down-regulation of TNFR1 is observed. Several authors have described 
increases in TNF receptors, ligands and related genes to be associated with induction of 
apoptosis, but there is growing evidence to suggest that TNFα promotes tumor 
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development and growth [76]. In a mouse model of metastatic colon adenocarcinoma, 
TNFα promotes tumor growth [77] and mice deficient in TNFα are resistant to skin 
carcinogenesis [78]. Furthermore, TNFR1 is the major mediator of TNFα-induced tumor 
formation in skin tumors [79] and during liver carcinogenesis [80]. Thus, while the initial 
decrease in TNFR1 induced at low concentrations of PXD101 may be considered as part 
of an activation of apoptotic pathways, the latter increase in TNFR1 at higher PXD101 
concentrations may be pro- or anti-apoptotic in T-24 bladder cancer cells. 
 
Figure 16: Signalling pathways in T-24 bladder cancer cells altered by survivin-
siRNA.  Red lettering indicates that either message or protein levels were modified 
by survivin-siRNA. 
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Similar to TNFR1 protein regulation, pro-caspase 8 levels are up-regulated at low 
concentrations of PXD101 and down-regulated at high PXD101 concentrations.  Caspase 
8 is an upstream caspase associated with a number of apoptotic pathways including 
TNFR1, APO2L/TRAIL and FASL.  It is believed that the TNFR1-induced pro-apoptotic 
signaling pathway requires the formation of two signaling complexes. A rapidly formed 
plasma membrane bound complex is composed of TNFR1, TRADD, RIP, TRAF2, and c-
IAP1 and triggers a NF-κB response, but no apoptosis. A second complex, which lacks 
TNFR1 but includes FADD and pro-caspases 8 and 10, subsequently forms in the 
cytoplasm. The complex containing pro-caspase 8 initiates apoptosis, provided that the 
NF-κB signal from complex I fails to induce the expression of anti-apoptotic proteins 
such as FLIPL.  FLIPL is an inhibitor of caspase 8 [81]. Thus, up-regulation of both 
TNFR1 and caspase 8 may be essential for apoptosis. 
Along with caspase 8, caspase 2 function as an upstream modulator that can 
trigger mitochondrial apoptotic pathways and release of cytochrome c [82]. Caspase-2 is 
required for the translocation of BAX/BAK1 to the mitochondria as well as release of 
mitochondrial proteins, which leads to apoptosis. Caspase 3 is a downstream effector 
caspase and is involved in Fas-mediated apoptosis. Decrease of pro-caspase levels with 
concomitant increase in lower molecular weight activated cleaved product is indicative of 
caspase pathway activation and induction of apoptosis. 
A profound decrease in protein levels of pro-caspases 2, 3 and 8 at higher 
PXD101 concentrations is noted, with a concomitant appearance of respective cleaved 
products, further supporting the induction of apoptosis in tumor cells. The cleaved 
products are only visualized at long film exposures though, deterring quantitative analysis 
 
 
33
of cleaved products. The initial up-regulation of pro-caspase 8 at low PXD101 
concentration may be due to an initial response by T-24 cells prior to cleavage to the 
activated product, since caspase 8 is an upstream modulator. 
The Bcl-2 family of proteins governs mitochondrial outer membrane 
permeabilisation and can be either pro-apoptotic or anti-apoptotic, and can induce or 
inhibit the release of cytochrome c in to the cytosol, which activates caspase-9 and 
caspase-3, leading to apoptosis. The protein levels of BAK1, a Bcl-2 related protein 
which promotes the release of cytochrome c, are decreased at high concentrations in T-24 
cells after treatment with PXD101. This is similar to our previous results, where 
expression of many Bcl gene products is altered in T-24 cells after treatment with 
survivin-siRNA. Survivin-siRNA treatment down-regulates mRNA of apoptosis 
facilitators, including BCL2-L11, -L12, -L13, BAK1 and BNIP1 (NIP-1, BCL interacting 
protein 1). BAK1 protein is initially up-regulated by survivin-siRNA, but by 72 hours 
BAK1 levels decrease. BNIP3, which induces both apoptotic and necrotic death, is also 
down-regulated in prostate carcinoma cells after treatment with ribosome-mediated 
inhibition of survivin expression. The complex regulation of these pro-and anti- apoptosis 
molecules by PXD101 and survivin-siRNA suggests that the relative concentrations of 
these molecules and the time course of activation or synthesis of these proteins may 
determine if a cell lives or dies [83]. 
In summary, T-24 cells treated with PXD101 are characterized by decreased 
growth and large numbers of cells undergoing apoptosis and arresting in G2/M phase of 
the cell-cycle. PXD101 treatment is also associated with changes in upstream 
mitochondrial apoptosis mediators, including TNFR1 and caspases 2 and 8, and 
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downstream apoptosis mediators, such as caspase 3, BAK1 and survivin. PXD101 
treatment of tumor cells is associated with a profound decrease in survivin and pro-
caspases’ levels, and with an increase in TNFR1 protein levels, both changes indicative 
of induction of apoptosis. BAK1 levels remain unchanged until high concentrations of 
the HDACI. This decrease in BAK1 levels, and in fact of all apoptosis related proteins at 
very high PXD101 concentrations, may be the result of PXD101 treatment or the T-24 
cells’ response to that treatment, such as generalized cell death with decreased protein 
synthesis. The down-regulation of survivin may cause T-24 cells to up-regulate TNF 
receptors and cleave pro-caspases in order to preserve their apoptotic phenotype.  
HDACIs have shown profound results in initiating tumor regression and 
symptomatic improvement in some heavily pre-treated patients at an advanced stage who 
have experienced multiple relapses. This regression has been achieved with a surprisingly 
low side-effect profile and a wide therapeutic index [84]. The impressive anti-tumor 
activity of HDACIs and their lack of toxicity at doses that effectively inhibit tumor 
growth strongly support these agents as a suitable molecular target for anticancer drug 
development. Therefore, the new HDACI PXD101, alone or in combination with 
inhibitors of other tumor relevant factors and with chemotherapies with complementary 
mechanisms of action, shows promise for its use as a suitable new agent for cancer 
treatment. 
This is the second report indicating up-regulation of TNFR1 with the use of any 
HDACI and the first to our knowledge that describes an initial increase in protein levels 
of apoptotic related proteins, only to be followed by a decrease in these levels. Future 
work on this project will involve investigating the effects of this new HDACI, PXD101, 
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using real time RT-PCR to assess mRNA levels of the apoptosis-related proteins 
analyzed above. An ELISA assay of the TNRF1 ligand, TNFα, will also be conducted on 
experiment media, to assess whether there is change in levels of this signaling molecule 
to further support our findings. A manuscript is currently in preparation to report these 
results and an abstract has been accepted to be presented at the national meeting of the 
Society of Genitourinary Surgeons. In addition, our lab has developed transgenic mice 
that over-express bladder specific survivin [85]. These mice demonstrate increased 
bladder inflammation and respond to a bladder carcinogen with accelerated tumor 
formation and shortened survival. The effects of PXD101 in these mice will be tested to 
determine if they have altered susceptibility to HDACIs and increased survival rates. 
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